Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Yale University's IRB has approved initiation of patient recruitment for Parts B and C of Clearmind Medicine's Phase I/II trial of CMND-100 in alcohol use disorder, enabling immediate enrollment expansion at Yale School of Medicine's Department of Psychiatry. The Yale site joins Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, with the Yale arm led by psychiatrist and addiction-medicine specialist Dr. Anahita Bassir Nia.
Key figures
- Drug Name
- CMND-100
- Phase Of Trial
- Phase I/II
- Dose cohorts
- 4
- Granted patents
- 32
- Part a participants
- 24
- Trial parts activated
- Parts B and C
- Serious adverse events
- 0
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.